Randomized controlled study of the histamine H3 inverse agonist MK-0249 in adult attention-deficit/hyperactivity disorder

• Published in: The journal of clinical psychiatry Vol. 73; no. 7; p. e891
• Main Authors: Herring, W Joseph, Wilens, Timothy E, Adler, Lenard A, Baranak, Christine, Liu, Kenneth, Snavely, Duane B, Lines, Christopher R, Michelson, David
• Format: Journal Article
• Language: English
• Published: United States 01.07.2012
• Subjects: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity - drug therapy; Biological Availability; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Histamine Agonists - adverse effects; Histamine Agonists - pharmacokinetics; Histamine Agonists - therapeutic use; Humans; Male; Metabolic Clearance Rate - physiology; Methylphenidate - adverse effects; Methylphenidate - pharmacokinetics; Methylphenidate - therapeutic use; Middle Aged; Personality Assessment; Pilot Projects; Quinazolinones - adverse effects; Quinazolinones - pharmacokinetics; Quinazolinones - therapeutic use; Young Adult

It has been suggested that the histamine subtype 3 receptor inverse agonists such as MK-0249 might be effective in treating attention-deficit/hyperactivity disorder (ADHD). We evaluated the effects of MK-0249 in adults with ADHD. A randomized, double-blind, placebo-controlled, incomplete block, 2-pe...